Innoviva
Innoviva, Inc. (Form: 8-K, Received: 04/26/2017 16:16:51)

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, DC  20549

 


 

FORM 8-K

 


 

Current Report Pursuant
to Section 13 or 15(d) of the
Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): April 20, 2017

 


 

INNOVIVA, INC.

(Exact Name of Registrant as Specified in its Charter)

 


 

Delaware
(State or Other Jurisdiction of Incorporation)

 

000-30319
(Commission File Number)

 

94-3265960
(I.R.S. Employer Identification Number)

 

2000 Sierra Point Parkway
Brisbane , California 94005
(650) 238-9600

(Addresses, including zip code, and telephone numbers, including area code, of principal executive offices)

 

 

(Former name or former address, if changed since last report)

 


 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o             Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o             Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o             Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o             Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company  o

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  o

 

 

 



 

Item 5.07 Submission of Matters to a Vote of Security Holders.

 

On April 20, 2017, Innoviva, Inc., a Delaware corporation (the “Company”), held its Annual Meeting of Stockholders (the “Annual Meeting”).  Set forth below are the proposals voted upon at the Annual Meeting, and the preliminary voting results received from IVS Associates, Inc. (“IVS”), the independent inspector of elections for the Annual Meeting.   These results are preliminary only and are subject to change based on the certification of the final voting results by IVS.  The Company will file an amendment to this Current Report on Form 8-K to disclose the final voting results within four business days after receiving IVS’s final certified report.

 

As of the close of business on February 24, 2017, the record date for the Annual Meeting, 109,201,168 shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”), were outstanding and entitled to vote.  Based on the preliminary results from IVS, at least 100,275,103 shares of Common Stock were voted in person or by proxy at the Annual Meeting, representing 91.83 percent of the shares entitled to be voted.

 

Proposal 1:            Election of Directors.

 

Based on the preliminary results from IVS, the Company’s stockholders elected the following nominees, constituting the Company’s full slate of nominees, to serve on the board of directors (the “Board of Directors”) until the next annual meeting of stockholders and until their successors have been duly elected or appointed: Michael W. Aguiar, Barbara Duncan, Catherine J. Friedman, Patrick G. LePore, Paul Pepe, James L. Tyree and William H. Waltrip. The preliminary tabulation from IVS of voting results for the election of directors and other proposals presented at the Annual Meeting is as follows:

 

Board of Directors Nominees:

 

Director

 

Votes For

 

Votes Withheld

 

Michael W. Aguiar

 

52,348,840

 

314,254

 

Barbara Duncan

 

99,630,634

 

644,469

 

Catherine J. Friedman

 

99,664,160

 

610,943

 

Patrick G. LePore

 

99,675,708

 

599,395

 

Paul Pepe

 

52,329,951

 

333,143

 

James L. Tyree

 

99,662,445

 

612,658

 

William H. Waltrip

 

52,330,709

 

332,385

 

 

Sarissa Capital Domestic Fund LP and certain of its affiliates (together, “Sarissa”) Nominees:

 

Director

 

Votes For

 

Votes Withheld

 

George W. Bickerstaff, III

 

47,609,581

 

2,428

 

Jules Haimovitz

 

31,412,005

 

16,200,004

 

Odysseas Kostas, M.D.

 

47,608,172

 

3,837

 

 

Proposal 2:            Advisory Vote to Approve Named Executive Officer Compensation.

 

Based on the preliminary results from IVS, the Company’s stockholders approved on a non-binding, advisory basis the compensation paid to the Company’s named executive officers, as disclosed in the Company’s definitive proxy statement on Schedule 14A filed with the United States Securities and Exchange Commission on March 22, 2017 (the “Proxy Statement”).

 

Votes For

 

Votes Against

 

Votes Abstaining

 

Broker Non-Votes

 

52,938,791

 

46,784,995

 

551,317

 

 

 

2



 

Proposal 3:            Advisory Vote on the Frequency of the Advisory Vote to Approve Named Executive Officer Compensation.

 

Based on the preliminary results from IVS, the Company’s stockholders approved on a non-binding, advisory basis that the non-binding, advisory vote on the compensation paid to the Company’s named executive officers shall occur once every year.

 

Votes For One Year

 

Votes For Two Years

 

Votes For Three Years

 

Abstain

 

99,339,624

 

39,682

 

264,254

 

631,543

 

 

Proposal 4:            Ratification of Appointment of Ernst & Young LLP.

 

Based on the preliminary results from IVS, the Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2017.

 

Votes For

 

Votes Against

 

Votes Abstaining

 

Broker Non-Votes

 

99,233,511

 

473,164

 

568,428

 

 

 

Proposal 5:            Stockholder Proposal on Repeal of New Bylaws.

 

At the Annual Meeting, representatives of Sarissa withdrew Sarissa’s stockholder proposal regarding the repeal of any provision of the Company’s Amended and Restated Bylaws adopted without stockholder approval following February 6, 2017. Therefore, such stockholder proposal was not presented for a vote at the Annual Meeting.

 

Item 8.01 Other Events.

 

On April 20, 2017, several Sarissa entities filed a Verified Complaint Pursuant to Section 225 of the Delaware General Corporation Law and for Specific Performance in the Delaware Court of Chancery, captioned Sarissa Capital Domestic Fund LP, et al. v. Innoviva, Inc. , C.A. No. 2017-0309-JRS (the “Specific Performance Litigation”). Sarissa alleges that it had entered into a binding agreement to settle its proxy contest in exchange for the inclusion of each of George W. Bickerstaff, III and Odysseas Kostas, M.D. on the Company’s Board of Directors. Sarissa seeks specific performance of the alleged agreement. With the complaint, Sarissa also filed a Motion for Entry of Status Quo Order, which seeks, among other things, to prevent the Company from engaging in any action outside the ordinary course of business without first giving Sarissa ten (10) business days’ notice until the Specific Performance Litigation is resolved. The Company believes the Specific Performance Litigation is without merit and intends to defend it vigorously.

 

3



 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

INNOVIVA, INC.

 

 

 

Date: April 26, 2017

By:

/s/ Eric d’Esparbes

 

 

Eric d’Esparbes

 

 

Chief Financial Officer

 

4